Streptokinase Dosing for Pulmonary Embolism
For acute pulmonary embolism, the recommended streptokinase dose is 250,000 IU as a loading dose over 30 minutes, followed by 100,000 IU/hour over 12-24 hours, or alternatively, an accelerated regimen of 1.5 million IU over 2 hours 1.
Standard Dosing Regimens
The 2020 ESC Guidelines provide two established streptokinase protocols 1:
Traditional Regimen
- Loading dose: 250,000 IU over 30 minutes
- Maintenance: 100,000 IU/hour infused over 12-24 hours
- This represents the original, well-validated approach
Accelerated Regimen
- Total dose: 1.5 million IU over 2 hours
- This shortened protocol offers faster administration while maintaining efficacy
Clinical Evidence Supporting the 2-Hour Regimen
The accelerated 2-hour streptokinase regimen demonstrates equivalent efficacy to alteplase with similar safety profiles 2. A randomized trial of 66 patients with massive PE (Miller score >17) compared 1.5 million IU streptokinase over 2 hours versus 100 mg alteplase over 2 hours. While alteplase showed faster improvement at 1 hour (33% vs 19% reduction in total pulmonary resistance), both agents achieved similar hemodynamic efficacy by 2 hours (38% vs 31%) and comparable pulmonary vascular obstruction reduction at 36-48 hours 2.
Additional research supports the accelerated approach:
- A prospective study of 40 patients using 1.5 million IU over 1 hour successfully reversed acute pulmonary arterial hypertension and right ventricular dysfunction in 35 patients (87.5%), with excellent 7-year outcomes 3
- Comparative trials show the 2-hour streptokinase regimen provides similar efficacy to 12-hour infusions but with more practical administration 4
Important Clinical Considerations
Anticoagulation Management
- Begin heparin infusion at the end of or immediately following streptokinase completion
- Wait until partial thromboplastin time or thrombin time returns to ≤2 times normal before starting heparin 5
Patient Selection
The decision to use thrombolysis depends on PE severity classification:
High-risk (massive) PE with hemodynamic instability:
- Clear indication for thrombolysis
- Includes cardiogenic shock, sustained hypotension, or cardiac arrest
- Mortality benefit outweighs bleeding risk
Intermediate-risk (submassive) PE:
- More controversial indication
- Consider in patients with RV dysfunction on echo or elevated cardiac biomarkers
- The 2026 AHA/ACC guidelines note that rescue thrombolysis for those who decompensate may be as effective as immediate thrombolysis, potentially avoiding unnecessary bleeding risk 6
Low-risk PE:
- Thrombolysis not indicated
- Anticoagulation alone is appropriate
Contraindications
Absolute contraindications include 1:
- History of hemorrhagic stroke or stroke of unknown origin
- Ischemic stroke in previous 6 months
- Central nervous system neoplasm
- Major trauma, surgery, or head injury in previous 3 weeks
- Active bleeding or bleeding diathesis
Practical Algorithm
- Confirm massive or high-risk PE (hemodynamic instability, shock, or cardiac arrest)
- Screen for absolute contraindications to thrombolysis
- Choose accelerated regimen for practical administration: 1.5 million IU streptokinase IV over 2 hours
- Monitor closely during infusion for bleeding complications and hemodynamic response
- Initiate heparin when coagulation parameters normalize (PTT/TT ≤2× normal)
Critical Pitfalls to Avoid
- Do not delay treatment in massive PE while awaiting confirmatory tests beyond initial imaging—mortality risk from untreated PE exceeds bleeding risk
- Do not use the traditional 12-24 hour regimen when the 2-hour accelerated protocol offers equivalent efficacy with more practical administration
- Do not automatically give thrombolysis to intermediate-risk PE—consider rescue thrombolysis strategy if patient decompensates, as this may provide similar benefit with less bleeding risk 6
- Do not forget to check for recent stroke history—this is an absolute contraindication even in massive PE
The accelerated 2-hour streptokinase regimen represents the optimal balance of efficacy, safety, and practical administration for acute pulmonary embolism requiring thrombolysis.